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Introduction
Experimental myocardial infarction (MI), direct gene
transfer with adeno-associated viral (AAV) vectors and
CMR in mice are powerful tools for studying the roles of
individual genes in MI and post-MI left ventricular (LV)
remodeling. Arterial spin labeling (ASL) enables the quan-
tification of myocardial perfusion (MP) by CMR, but is
sensitive to variable heart rates and irregular respiration,
prohibiting accurate measurement early after MI. We
developed a cardio-respiratory gated (CRG) ASL method
that is insensitive to these factors to measure MP in mice.
Purpose
The objective of this study was to test the hypotheses that
AAV9-mediated overexpression of extracellular superox-
ide dismutase (EcSOD) from the cardiac Troponin-T
(cTnT) promoter would increase capillary density and
protect the heart against myocardial infarction (MI). Fur-
thermore, we tested the hypothesis that an improved
method of ASL could quantitate the elevation in MP
resulting from increased capillary density.
Methods
CRG-ASL was developed on a 7 T MR system and
employed to measure MP both before and 4 wks after
gene therapy. AAV vectors were cross-packaged into AAV9
capsids expressing EcSOD or eGFP from the cTnT pro-
moter (AcTnTEcSOD or AcTnTeGFP), and were injected
IV into 4-5 week-old C57Bl/6 mice (3 × 1011 vp/mouse).
Four weeks after injection, MI was induced by a 30 min
coronary occlusion. Infarct size and area at risk (A@R)
were measured 24 h later by TTC and Phthalo blue stain-
ing, respectively. Capillary density was measured 4 wks
post injection in remote myocardium immunostained for
CD31.
Results
MP as measured by CRG-ASL increased by 30% from 4.3
+ 0.5 before to 5.6 + 0.3 ml/g-min at 4 wks post AcTnTEc-
SOD injection (P < 0.05), then dropped to 2.4 + 0.6 ml/g-
min in the infarct zone 24 h post-MI. A single IV injection
of AcTnTEcSOD provided uniform EcSOD overexpression
throughout the myocardium (Panel A). Infarct size (as %
A@R, Panel B) was reduced by 45% in EcSOD mice (33.9
+ 6.3, mean + SEM, n = 4) compared to eGFP mice (61.3
+ 3.8, n = 4, P < 0.05). Capillary density was 23.6% higher
in EcSOD mice (5446 + 368/mm2) compared to eGFP
mice (4405 + 271/mm2, P < 0.05), Figure 1.
Conclusion
CRG-ASL quantifies the increase in MP resulting from car-
dioprotective gene therapy with EcSOD. Transcriptional
targeting with the cTnT promoter in combination with the
high-efficiency AAV9 capsid provides cardioprotective
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gene therapy from a single IV injection. AAV9-mediated
overexpression of EcSOD from the cTnT promoter signifi-
cantly increases capillary density, improves myocardial
perfusion and reduces infarct size in the murine heart.
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